

**ASPARTATE TO PLATELETS RATIO INDEX (APRI TEST)
AS A NON-INVASIVE MARKER FOR EVALUATION
OF LIVER FIBROSIS IN PATIENTS WITH
CHRONIC HCV AND HBV**

THESIS

**Submitted For Partial Fulfillment of the Master Degree in
INTERNAL MEDICINE**

By

ALAA EL DIN FATHI ABD EL MONEIM HELMI
M.B.B.Ch. Faculty of Medicine - Cairo University

Supervised By

Prof.Dr. OSAMA ABO EL FOTOH EL SAYED
Professor of Internal Medicine
Faculty of Medicine - Ain Shams University

Prof.Dr. NOHA ABD EL RAZEK EL NAKKEB
Prof. of Internal Medicine
Faculty of Medicine - Ain Shams University

Assist. Prof. Dr. AMIR HELMY SAMY
Assist. Prof. of Internal Medicine
Faculty of Medicine - Ain Shams University

**Faculty of Medicine
Ain Shams University**

2014

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَقُلْ اَعْمَلُوا فَسَيَرَى اللَّهُ عَمَلَكُمْ وَرَسُولُهُ
وَالْمُؤْمِنُونَ

صدق الله العظيم

سورة التوبة آية (١٠٥)



Acknowledgement

First, thanks are all due to **Allah** for Blessing this work until it has reached its end, as a part of his generous help throughout our life.

I would like to express my deep gratitude and appreciation to **Prof. Dr. Osama Abo El Fotoh El Sayed**, Professors of Internal Medicine, Faculty of Medicine, Ain Shams University, for his great supervision, great help, available advises, continuous encouragement and without his support it was impossible for this study to be achieved in this form. I had the privilege to benefit from his great knowledge, and it is an honor to work under his guidance and supervision.

I am sincerely express my great appreciation to **Prof. Dr. Noha Abd El Razeq El Nakeeb**, Professors of Internal Medicine, Faculty of Medicine, Ain Shams University, for her efforts and all advices she offered me to make this work possible.

I am deeply thankful to **Prof. Dr. Amir Helmy Samy**, Assistant prof of Internal Medicine, Faculty of Medicine, Ain Shams University, for his meticulous revision, constant support and valuable advice.

I am deeply thankful to **All the Patients** that shared in the study and without their cooperation; this work would never be done.

I am deeply thankful to **Yaseen Abd El Ghaffar Center for Liver Diseases and Researches** for the support and assistance.

I am also thankful to my friend **Dr. Ismail Qassem, Liver Institute, Cairo** for his sincere and great help.

Last but not least, I dedicate this work to **the soul of my mother and all my family members ; my father, my brothers, my sisters, my wife, my kids , my friends and colleagues**, whom without their sincere emotional support; this work could not have been completed.



ALAA EL DIN FATHI, 2014

List of Contents

Content	Page
<i>Acknowledgement</i>	
<i>List of Abbreviations</i>	III
<i>List of Tables</i>	V
<i>List of Figures</i>	VII
<i>Abstract</i>	X
<i>Introduction</i>	1
<i>Aim of the work</i>	4
<i>Review of Literature</i>	
Chapter 1: Hepatitis B	5
Epidemiology and history of HBV.	6
Transmission of HBV.	7
Clinical Manifestations of Hepatitis B.	11
Virology of Hepatitis B.	20
Diagnostic tests for acute and chronic hepatitis B.	24
Treatment of chronic hepatitis B.	36
Chapter 2:Hepatitis C	84
Epidemiology and history of HCV.	84
Transmission of HVC.	84
Clinical Manifestations of Hepatitis C.	87
Virology of Hepatitis C.	93
Diagnostic tests for acute and chronic hepatitis C.	99
Treatment of chronic hepatitis C.	105
Chapter 3:Liver fibrosis	136
Histology of the Liver.	137
Pathogenesis of Liver Fibrosis.	142
Some Clinical Aspects of Liver Fibrosis.	152
Importance of staging and grading of liver fibrosis.	155

Chapter 4:Diagnosis of liver fibrosis	157
Liver biopsy as an Invasive method for diagnosis of liver fibrosis	158
Noninvasive assessment of liver fibrosis	162
Liver imaging techniques	162
Serum markers:	163
*A. Indirect markers	164
*B. Direct markers of liver fibrogenesis	169
Chapter 5:APRI TEST	182
<i>Patient and Method</i>	186
<i>Results</i>	194
<i>Discussion</i>	222
<i>Summary</i>	230
<i>Conclusion</i>	233
<i>Recommendations</i>	234
<i>References</i>	235
<i>Arabic Summary</i>	١

List of Abbreviations

ADV	:	Adefovir Dipivoxil.
APRI Test	:	ASPARTATE TO PLATELET RATIO INDEX Test.
AUC	:	Area Under Curve.
AST	:	Aspartate Transferase.
ALT	:	Alanine Transferase.
BOC	:	Boceprevir.
B.M.I	:	Body Mass Index.
C.B.C	:	Complete blood Cytology.
C.T	:	Computerized tomography.
ECM	:	Extra cellular matrix.
ETV	:	<u>Entecavir</u> .
HBIG	:	Hepatitis B-immunoglobulin.
HBV	:	Hepatitis B. virus.
HBVcAg	:	Hepatitis B core antigen .
HBVcAb	:	Hepatitis B core antibody.
HBVeAg	:	Hepatitis B envelop antigen.
HBVeAb	:	Hepatitis B envelop antibody.
HBVsAg	:	Hepatitis B surface antigen.
HBVsAb	:	Hepatitis B envelop antibody.
HCC	:	Hepato Cellular Carcinoma.
H.C.V	:	Hepatitis C. Virus.
H.C.Vab	:	Hepatitis C virus Antibodies.
HIV	:	Human Immuno-deficiency Virus.
HSCs	:	Hepatic Stellate Cells.
LDL	:	Low Density Lipoprotein.
LdT	:	Telbivudine.
LMD	:	Lamivudine.
MELD	:	Model for End-Stage Liver Disease.
MHz	:	Mega Hertiz.
N.A.S.H	:	None Alcoholic Steato-hepatitis.
PBC	:	Primary Biliary Cirrhosis.
P.C.R	:	Polymerase Chain Reaction.

PEG-INF α	:	Pegylated Interferon α .
PSC	:	Primary Sclerosing Cholangitis.
RAVs	:	Amino Acid Variants.
RBV	:	Ribavirin.
ROC	:	Receiver Operating Characteristics.
TDF	:	Tenofovir Disoproxil Fumarate.
TLV	:	Telaprevir.
VLDL	:	Very Low Density Lipoprotein.
ULN	:	Upper Limit of Normal.
U.S	:	Ultra Sound.

List of Tables

Table	Content	Page
I	Key guideline recommendations for indication for antiviral treatment of HBV infection.	37
II	Overview of interferon and oral antiviral drugs currently approved for the treatment of HBV infection.	48
III	Recommendations for the use of nucleos(t)ide analogs in clinical practice.	49
IV	Predictors of response to antiviral therapy.	59
V	Recommendation for laboratory tests for monitoring antiviral therapy.	66
VI	Recommendations in secondary treatment failure of HBV polymerase inhibitors.	77
VII	Child -Pugh classification of severity of liver disease.	92
VIII	Size and main function of HCV proteins.	95
IX	Relevant definitions for HCV treatment.	108
X	Approved drugs for the treatment of chronic hepatitis C.	109
XI	Phase III studies with BOC or TLV treatment regimens in treatment naïve patients with HCV genotype.	112
XII	Phase III studies with BOC or TLV treatment regimens in treatment-experienced patients infected with HCV genotype 1.	119
XII	Common side effects (>5% of patients) recorded in the PEG-IFN/RBV/PI trials.	124
XIV	Recommended combination therapy.	129
XV	Ribavirin Dose Modification Guideline for Coadministration with Sofosbuvir.	130
XVI	Commonly used liver fibrosis staging scores.	161
XVII	Initial reports of indirect serum assays for hepatic fibrosis.	178
XVIII	Initial reports of direct serum assays for hepatic fibrosis.	179
1	Demographic and laboratory data for all participants in the study	195
2	Gender distribution for all studied cases.	197

3	Stages of fibrosis among patients using Liver biopsy in HCV (METAVIR SCORE) and Fibroscan in HBV patients.	197
4	Ultrasonographic findings of the studied patients.	198
5	The Demographic and laboratory data of non-fibrotic (F0) VS fibrotic patients (F 1-2-3-4) in chronic HCV patients (group 1).	199
6	The Demographic and laboratory data of non-fibrotic (F0) VS fibrotic patients (F 1-2-3-4) in chronic HBV patients (group 2).	200
7	The Demographic and laboratory data of non-significant fibrosis (F0-1) VS significant fibrosis patients (F 2-3-4) in chronic HCV patients (group 1).	201
8	The Demographic and laboratory data of non-significant fibrosis (F0-1) VS significant fibrosis (F 2-3-4) in chronic HBV patients (group 2).	202
9	The Demographic and laboratory data of non-cirrhotic (F0-1-2-3) VS cirrhotic patients (F4) in chronic HCV patients (group 1).	203
10	The Demographic and laboratory data of non-cirrhotic (F0-1-2-3) VS cirrhotic patients (F4) in chronic HBV patients (group 2).	204
11	The correlation between demographic and variable laboratory dataand the stage of fibrosis in HCV patients (group 1) and HBV patients (group 2).	205
12	Univariate analysis of different parameters associated with each stage of fibrosis in chronic HCV patients (group 1).	206
13	Multi-variate analysis of different parameters associated with each stage of fibrosis in chronic HCV patients (group 1).	207
14	Univariate analysis of different parameters associated with each stage of fibrosis in chronic HBV patients(group 2).	208
15	Multi-variate analysis of different parameters associated with each stage of fibrosis in chronic HBV patients(group 2)	209
16	Cut off, Sensitivity and Specificity of APRI test with different stages of liver fibrosis in chronic HCV patients (group1).	212
17	Cut off values, Sensitivity and Specificity of APRI test with different stages of liver fibrosis in chronic HBV patients (group 2).	217

List of Figures

Figure	Content	Page
I	Schematic representation of the HBV virion and non-infectious empty subviral particles.	23
II	Indication for antiviral treatment (German guidelines for the treatment of chronic HBV infection).	41
III	Possible endpoints of treatment of chronic HBV infection. After achieving HBeAg or HBsAg seroconversion, antiviral treatment can be stopped.	43
IV	Treatment algorithm for chronic HBV infection according to the German Guidelines.	47
V	1-year efficacy of medications currently approved for the treatment of chronic HBV.	51
VI	Possible courses of HBV DNA levels during treatment with nucleoside or nucleotide analogs	60
VII	On-treatment prediction of treatment response by HBsAg levels.	63
VIII	The level of HBsAg levels after 12 weeks of treatment with PEG-IFN α -2a is predictive for HBeAg seroconversion six months after treatment.	64
IX	Proportion of patients with undetectable HBV DNA after 48 or 52 weeks of treatment.	70
X	Cumulative incidence of HBV polymerase inhibitor resistance.	74
XI	Resistance patterns of different antiviral drugs used for the treatment of chronic HBV.	75
XII	Mutations in the HBV polymerase.	81
XII	Antiviral potency and genetic resistance barrier of currently approved HBV polymerase inhibitors.	83
XIV	Genome organization and polyprotein processing.	94
XV	Model of the HCV lifecycle.	96
XVI	Detection limits and linear dynamic ranges of commercially available HCV RNA detection assays.	102
XVIIA	Treatment with BOC/PEG-IFN/RBV.	110
XVIIB	Treatment with TLV/PEG-IFN/RBV.	111
XVIII	Suggestion to use the lead-in strategy for individualization of treatment in patients with HCV genotype.	116

XIX	Different scenarios of treatment failure to antiviral therapy in chronic hepatitis C.	118
XX	Recommendation for treatment of HCV genotypes 2 and 3.	121
XXI	Suggestion for treatment of HCV genotypes 4, 5, and 6.	122
XXII	(A) Normal liver, (B) Injured liver with fibrosis.	139
XXIII	Sequence of events involved in fibrosis.	145
XXIV	The most important factors involved in the activation of hepatic stellate cell during liver injury and natural course of liver fibrosis.	146
XXV	HSCs activation.	149
XXVI	Potential clinical decision algorithm for safer liver biopsies in patients with chronic viral hepatitis.	181
1	AAR values in different stages of fibrosis in HCV (group 1).	210
2	APRI values in different stages of fibrosis in HCV (group 1).	210
3	AAR values in different stages of fibrosis in HBV (group 2).	211
4	APRI values in different stages of fibrosis in HBV (group 2).	211
5	Showing ROC curve , cutoff point and diagnostic parameters for discriminating patients with non-fibrotic group (F0) from fibrotic group (F1-2-3-4) in chronic HCV patients (group 1).	213
6	Spearman's linear correlation between APRI test and non or mild fibrosis ($F < 1$) in in chronic HCV patients (group 1).	213
7	Showing ROC curve , cutoff point and diagnostic parameters for discriminating patients with non-significant fibrotic group (F0-1) from significant fibrotic group (F2-4) in chronic HCV patients (group 1).	214
8	Spearman's linear correlation between APRI test and significant fibrosis ($F \geq 2$) in chronic HCV patients(group 1).	214
9	Showing ROC curve , cutoff point and diagnostic parameters for discriminating patients with non-cirrhotic group (F0-1-2-3) from cirrhotic group (F4) in chronic HCV patients (group 1)	215
10	Spearman's linear correlation between APRI test and cirrhotic group ($F = 4$) in chronic HCV patients (group 1)	215
11	Spearman's linear correlation between AAR test and stages of fibrosis in in chronic HCV patients (group 1).	216
12	Spearman's linear correlation between APRI test and stages of fibrosis in in chronic HCV patients (group 1).	216

13	Showing ROC curve, cutoff point and diagnostic parameters for discriminating patients with non-fibrotic group (F0) from fibrotic group (F1-2-3-4) in chronic HBV patients (group 2).	218
14	Spearman's linear correlation between APRI test and mild fibrosis ($F < 1$) in in chronic HBV patients (group 2).	218
15	Showing ROC curve, cutoff point and diagnostic parameters for discriminating patients with non-significant fibrotic group (F0-1) from significant fibrotic group (F2-4) in chronic HBV patients (group 2).	219
16	Spearman's linear correlation between APRI test and significant fibrosis ($F \geq 2$) in chronic HBV patients (group 2).	219
17	Showing ROC curve, cutoff point and diagnostic parameters for discriminating patients with non-cirrhotic group (F0-1-2-3) from cirrhotic group (F4) in chronic HBV patients (group 2).	220
18	Spearman's linear correlation between APRI test and cirrhotic group ($F = 4$) in chronic HBV patients (group 2).	220
19	Spearman's linear correlation between AAR test and stages of fibrosis in in chronic HBV patients (group 2).	221
20	Spearman's linear correlation between APRI test and stages of fibrosis in in chronic HBV patients (group 2).	221